论文部分内容阅读
贝伐单抗属抗肿瘤新药,以血管内皮生长因子(VEGF)为靶点,抑制VEGF活性,减少新生血管的形成,发挥抗纤维、血管增生的作用,从而限制肿瘤的生长,发挥抗肿瘤作用。眼部有许多与VEGF相关的新生血管性疾病,依据贝伐单抗具有对新生血管生成的抑制作用,近年来,许多眼科专家尝试将其用于翼状胬肉以及各种眼内、眼表新生血管性疾病的治疗,取得一定疗效,但尚属探讨领域,现对该药的药理原理及其在翼状胬肉治疗方面予以综述。
Bevacizumab is a new anti-tumor drug targeting vascular endothelial growth factor (VEGF), inhibiting VEGF activity, reducing the formation of new blood vessels and exerting anti-fibrotic and vascular hyperplasia effects, thereby limiting tumor growth and exerting antitumor effects . In the eye, there are many new vascular diseases associated with VEGF. According to the suppressive effect of bevacizumab on angiogenesis, in recent years, many ophthalmologists have tried to use it for pterygium and various intraocular and ocular surface newborn Vascular disease treatment, and achieved a certain effect, but it is still the area of exploration, the pharmacological principles of the drug and its treatment of pterygium to be reviewed.